Ms Patricia Turner, PD in Marvell, AR - Pharmacist

Ms Patricia Turner, PD is a Pharmacist based in Marvell, Arkansas. Ms Patricia Turner is licensed to practice in Arkansas (license number PD07340) and her current practice location is 406 S Mill St, Marvell, Arkansas. She can be reached at her office (for appointments etc.) via phone at (870) 829-9116.

NPI number for Ms Patricia Turner is 1962154005 and her current mailing address is 406 S Mill St, Marvell, Arkansas. She does not participate in medicare program and thus does not accept medicare assignments. Her NPI Number is 1962154005.

Contact Information

	Ms Patricia Turner, PD
	406 S Mill St, Marvell, AR 72366-9302
	(870) 829-9116
	(870) 829-1152

Healthcare Provider's Profile

Full Name	Ms Patricia Turner
Gender	Female
Speciality	Pharmacist
Location	406 S Mill St, Marvell, Arkansas
Accepts Medicare Assignments	Does not participate in Medicare Program. She may not accept medicare assignment.

NPI Data:

NPI Number: 1962154005
Provider Enumeration Date: 01/20/2022
Last Update Date: 01/20/2022

Medical Identifiers

Medical identifiers for Ms Patricia Turner such as npi, medicare ID, medicare PIN, medicaid, etc.

Identifier	Type	State	Issuer
1962154005	NPI	-	NPPES

Medical Taxonomies and Licenses

Taxonomy	Type	License (State)	Status
183500000X	Pharmacist	PD07340 (Arkansas)	Primary

Medicare Part D Prescriber Enrollment

Any physician or other eligible professional who prescribes Part D drugs must either enroll in the Medicare program or opt out in order to prescribe drugs to their patients with Part D prescription drug benefit plans. Ms Patricia Turner is NOT enrolled with medicare and thus cannot prescribe medicare part D drugs to patients with medicare part D benefits.

Mailing Address and Practice Location

Mailing Address	Practice Location Address
Ms Patricia Turner, PD 406 S Mill St, Marvell, AR 72366-9302 Ph: (870) 829-1168	Ms Patricia Turner, PD 406 S Mill St, Marvell, AR 72366-9302 Ph: (870) 829-9116

News Archive

AMRI selects compound for advanced preclinical testing in treatment of IBS

AMRI today announced the selection of a compound from its proprietary research program for the treatment of irritable bowel syndrome (IBS) for advanced preclinical testing, with the goal of submitting an Investigational New Drug Application (IND) with the U.S. Food and Drug Administration (FDA) in 2011.

Modified herpes virus - a killer of cancer cells

Scientists have developed a virus specifically designed to target cancer tissue while not affecting normal healthy tissue.

Distinct origin of ADHD identified In children with history of traumatic brain injury

According to a study in Biological Psychiatry, physical brain injury in children contributes to the development of attention-deficit/hyperactivity disorder (ADHD), distinct from genetic risk for the disorder.

New federal guidelines on breast cancer screening: Stanford experts disagree

At a recent community education program, Stanford experts on women's cancer disagreed with controversial new federal guidelines on breast cancer screening. The new guidelines, released in November by the U.S. Preventive Services Task Force, would delay a woman's first mammogram by 10 years, reduce future screenings from annual to every other year, and end them after age 74.

Ms Patricia Turner, PD - Pharmacist in Marvell, AR